Literature DB >> 21245090

Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.

Maxim A Moroz1, Tatiana Kochetkov, Shangde Cai, Jiyuan Wu, Mikhail Shamis, Jayasree Nair, Elisa de Stanchina, Inna Serganova, Gary K Schwartz, Debabrata Banerjee, Joseph R Bertino, Ronald G Blasberg.   

Abstract

PURPOSE: To determine whether treatment response to the Aurora B kinase inhibitor, AZD1152, could be monitored early in the course of therapy by noninvasive [(18)F]-labeled fluoro-2-deoxyglucose, [(18)F]FDG, and/or 3'-deoxy-3'-[(18)F]fluorothymidine, [(18)F]FLT, PET imaging. EXPERIMENTAL
DESIGN: AZD1152-treated and control HCT116 and SW620 xenograft-bearing animals were monitored for tumor size and by [(18)F]FDG, and [(18)F]FLT PET imaging. Additional studies assessed the endogenous and exogenous contributions of thymidine synthesis in the two cell lines.
RESULTS: Both xenografts showed a significant volume-reduction to AZD1152. In contrast, [(18)F]FDG uptake did not demonstrate a treatment response. [(18)F]FLT uptake decreased to less than 20% of control values in AZD1152-treated HCT116 xenografts, whereas [(18)F]FLT uptake was near background levels in both treated and untreated SW620 xenografts. The EC(50) for AZD1152-HQPA was approximately 10 nmol/L in both SW620 and HCT116 cells; in contrast, SW620 cells were much more sensitive to methotrexate (MTX) and 5-Fluorouracil (5FU) than HCT116 cells. Immunoblot analysis demonstrated marginally lower expression of thymidine kinase in SW620 compared with HCT116 cells. The aforementioned results suggest that SW620 xenografts have a higher dependency on the de novo pathway of thymidine utilization than HCT116 xenografts.
CONCLUSIONS: AZD1152 treatment showed antitumor efficacy in both colon cancer xenografts. Although [(18)F]FDG PET was inadequate in monitoring treatment response, [(18)F]FLT PET was very effective in monitoring response in HCT116 xenografts, but not in SW620 xenografts. These observations suggest that de novo thymidine synthesis could be a limitation and confounding factor for [(18)F]FLT PET imaging and quantification of tumor proliferation, and this may apply to some clinical studies as well. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245090      PMCID: PMC3079195          DOI: 10.1158/1078-0432.CCR-10-1430

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  52 in total

1.  Protein kinase Cdelta mediates insulin-induced glucose transport in primary cultures of rat skeletal muscle.

Authors:  L Braiman; A Alt; T Kuroki; M Ohba; A Bak; T Tennenbaum; S R Sampson
Journal:  Mol Endocrinol       Date:  1999-12

2.  An improved method for staining cell colonies in clonogenic assays.

Authors:  Kishore Guda; Leanna Natale; Sanford D Markowitz
Journal:  Cytotechnology       Date:  2007-06-12       Impact factor: 2.058

3.  [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.

Authors:  Seung Jin Choi; Jae Seung Kim; Jeong Hoon Kim; Seung Jun Oh; Jeong Gyo Lee; Chang Jin Kim; Young Shin Ra; Jeong Seok Yeo; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-15       Impact factor: 9.236

4.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Authors:  Andrew A Mortlock; Kevin M Foote; Nicola M Heron; Frédéric H Jung; Georges Pasquet; Jean-Jacques M Lohmann; Nicolas Warin; Fabrice Renaud; Chris De Savi; Nicola J Roberts; Trevor Johnson; Cyril B Dousson; George B Hill; David Perkins; Glenn Hatter; Robert W Wilkinson; Stephen R Wedge; Simon P Heaton; Rajesh Odedra; Nicholas J Keen; Claire Crafter; Elaine Brown; Katherine Thompson; Stephen Brightwell; Liz Khatri; Madeleine C Brady; Sarah Kearney; David McKillop; Steve Rhead; Tony Parry; Stephen Green
Journal:  J Med Chem       Date:  2007-03-21       Impact factor: 7.446

5.  AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Authors:  Robert W Wilkinson; Rajesh Odedra; Simon P Heaton; Stephen R Wedge; Nicholas J Keen; Claire Crafter; John R Foster; Madeleine C Brady; Alison Bigley; Elaine Brown; Kate F Byth; Nigel C Barrass; Kirsten E Mundt; Kevin M Foote; Nicola M Heron; Frederic H Jung; Andrew A Mortlock; F Thomas Boyle; Stephen Green
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

Review 6.  Aurora kinases as anticancer drug targets.

Authors:  Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo N Lara; David R Gandara
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

7.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

8.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

9.  A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.

Authors:  Jiahe Tian; Xiaofeng Yang; Lijuan Yu; Ping Chen; Jun Xin; Liming Ma; Huiru Feng; Yieyin Tan; Zhoushe Zhao; Wenkai Wu
Journal:  J Nucl Med       Date:  2008-01-16       Impact factor: 10.057

10.  Kinase Inhibitor 4 Minisymposium summary.

Authors:  Janet E Dancey
Journal:  Expert Rev Anticancer Ther       Date:  2009-07       Impact factor: 4.512

View more
  14 in total

1.  Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

Authors:  Sarah R Mudd; Kimberley D Holich; Martin J Voorbach; Todd B Cole; David R Reuter; Paul Tapang; Gail Bukofzer; Arunava Chakravartty; Cherrie K Donawho; Joann P Palma; Gerard B Fox; Mark Day; Yanping Luo
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

2.  Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype.

Authors:  Inna Serganova; Asif Rizwan; Xiaohui Ni; Sunitha B Thakur; Jelena Vider; James Russell; Ronald Blasberg; Jason A Koutcher
Journal:  Clin Cancer Res       Date:  2011-08-15       Impact factor: 12.531

3.  Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment.

Authors:  Chun-Yi Wu; Lin-Shan Chou; Pei-Chia Chan; Chung-Hsien Ho; Ming-Hsien Lin; Chih-Chieh Shen; Ren-Shyan Liu; Wuu-Jyh Lin; Hsin-Ell Wang
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

4.  Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.

Authors:  Jennifer G Whisenant; J Oliver McIntyre; Todd E Peterson; Hakmook Kang; Violeta Sánchez; H Charles Manning; Carlos L Arteaga; Thomas E Yankeelov
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

Review 5.  Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.

Authors:  Mette Munk Jensen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

6.  Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.

Authors:  Mette Munk Jensen; Kamille Dumong Erichsen; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Maxwell Sehested; Liselotte Højgaard; Andreas Kjær
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

7.  [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.

Authors:  Christopher Cawthorne; Natalie Burrows; Roben G Gieling; Christopher J Morrow; Duncan Forster; Jamil Gregory; Marc Radigois; Alison Smigova; Muhammad Babur; Kathryn Simpson; Cassandra Hodgkinson; Gavin Brown; Adam McMahon; Caroline Dive; Duncan Hiscock; Ian Wilson; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

8.  Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.

Authors:  Eliot T McKinley; Gregory D Ayers; R Adam Smith; Samir A Saleh; Ping Zhao; Mary Kay Washington; Robert J Coffey; H Charles Manning
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

9.  [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.

Authors:  Mette Munk Jensen; Kamille Dumong Erichsen; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Maxwell Sehested; Liselotte Højgaard; Andreas Kjær
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy.

Authors:  Junzhong Xu; Ke Li; R Adam Smith; John C Waterton; Ping Zhao; Heidi Chen; Mark D Does; H Charles Manning; John C Gore
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.